A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
TPG to sell Cancer Treatment Services International for $283 million
on May 21, 2019 at 12:47 am
Mumbai: US-based private equity firm TPG Capital on Tuesday signed a definitive agreement to sell its chain of cancer treatment hospitals, Cancer Treatment Services International (CTSI), to silicon ... […]
Varian Announces Definitive Agreement to Acquire Cancer Treatment Services International
on May 21, 2019 at 12:36 am
Advances Varian Toward Being a Broad-Based Cancer Solutions Company; Updates Annual Guidance Acquisition key highlights - Brings Varian closer to the patient and provider to gain clinical data and ... […]
TPG to sell Cancer Treatment Services to US firm Varian for $283 mn
on May 21, 2019 at 12:11 am
TPG Growth, the middle market and growth equity platform of alternative asset firm TPG, has signed an agreement to sell Cancer Treatment Services International (CTSI) to US-based Varian Medical ... […]
Nearly all women treated for breast cancer suffer from health problems, finds study
on May 20, 2019 at 11:46 pm
Nearly all women who have been treated for non-metastatic breast cancer suffer from health problems after primary treatment. The problems reported by women include fatigue, tingling in the hands and ... […]
Cancer survivors share stories of hope at Flagler's Relay for Life
on May 20, 2019 at 11:27 pm
While no one wants to be diagnosed with cancer, families and friends look for ways to buoy the spirits of those going through treatment and the annual relay is an opportunity to remind patients and ... […]
Potential new therapy takes aim at a lethal esophageal cancer's glutamine addiction
on May 20, 2019 at 11:22 pm
This breakthrough is now opening the doorway to new treatments for an otherwise lethal cancer. The findings of the National Institutes of Health (NIH)-funded study are reported in Nature ... […]
Clinical trial determines how proton radiotherapy can be used in early stage breast cancer
on May 20, 2019 at 10:59 pm
"Additionally, we'll evaluate side effects patients experience as well as cancer recurrence rates." Proton radiotherapy is a form of radiation treatment used for certain types of cancers and lymphomas ... […]
Predicting breast cancer metastasis by cell behavior instead of genetics
on May 20, 2019 at 6:13 am
Cancer treatments are strenuous on the body and can be costly. Some patients need chemotherapy, radiation, surgery, targeted therapies, or a combination of all of the above. MAqCI can help ... […]
Future Growth: Kidney Cancer Treatment Drugs Market Could Be $xx Billion Market Opportunity by 2025
on May 20, 2019 at 4:05 am
May 20, 2019 (marketresearchupdates.com via COMTEX) -- Global Kidney Cancer Treatment Drugs Market Report, History and Forecast 2014-2025, Breakdown Data by Companies, Key Regions, Types and ... […]
via Bing News